& even more important is, page-14

"Celera expects to use this panel of biomarkers when CT (computer axial tomography) tests show
irregularities in patients"

I read this as now meaning ... diagnostic GIANT QUEST expects to use this panel.

If that does not equate to cash flow what does? In the near term (and by that I mean 12 months) all that is needed is sufficient cash flow to get the diluton monkey off the company's back.

I also note that the 6 panel maker should be more profitable than the 9 marker panek to come (if the latter contains MDK) because the standard royalty (range 7% to 15%) would require less splitting in my humble and uninformed opinion.

IF the market is asleep to the level of progress on several piplines, and the ability Quest to potentially speed up pipelines associated with CDY's industrial property then so be it! I did top up.

cheers